Lundbeck acquires phase I-ready candidate from South Korean firm

Danish pharmaceutical giant Lundbeck has acquired exclusive rights to a biotherapy candidate for treating neurological diseases from Aprilbio, in a deal that may cost up to USD 448m.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck CEO considers stepping up marketing of Vyepti
For subscribers
Lundbeck silent on shutdown of Indian operations
For subscribers